NCT00670657View on ClinicalTrials.gov

CRITIC - Treatment of Candidemia and Invasive Candidiasis

PHASE4CompletedINTERVENTIONAL

Enrollment

39

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

January 31, 2009

Conditions

CandidemiaInvasive Candidiasis

Interventions

DRUG

AmBisome

Patients will receive 2mg/kg/day IV daily administration of AmBisome® over 30-60 minutes as a reaction to signs/symptoms and positive Candida culture

Trial Locations (1)

20146

Gilead Sciences Srl, Milan

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY